US FDA Delay For Abecma In Early MM Gives Carvykti Time To Catch Up
Executive Summary
Bristol Myers and 2seventy bio are hoping Abecma will be the first CAR-T therapy for earlier lines of multiple myeloma, but an advisory committee meeting will hold up the sBLA.